Pharmacology Watch
RSSArticles
-
Report: Access to Biosimilars May Increase Access to Treatment for Cancer Patients Worldwide
A new biosimilar to trastuzumab has proven effective in treating women without prior treatment for ERBB2 (HER2)-positive metastatic breast cancer.
-
FDA Actions
Agency approves prasterone to treat women with moderate to severe dyspareunia due to menopause-related vulvar and vaginal atrophy.
-
Notable COX-2 Inhibitor Carries Same CV Risks as Traditional NSAIDs
However, promising report not without its critics.
-
Exploring Therapies to Reduce Pelvic and Hip Fractures
More evidence suggests thiazides improve bone strength and reduce fracture risk by exerting a positive effect on calcium balance and perhaps a direct stimulatory effect on osteoblasts.
-
PPI Use and Community-acquired Pneumonia Risks
A new study concluded that the previously noted association between proton pump inhibitor use and community-acquired pneumonia is “likely to be due entirely to confounding factors.”
-
High-dose Statins as a Secondary Prevention
Researchers found there was a graded association between intensity of statin therapy and mortality in patients suffering from atherosclerotic cardiovascular disease.
-
USPSTF Updates Guideline on Screening for Lipid Disorders in Adults
New guideline recommends low- to moderate-dose statins in adults 40-75 years of age without a history of cardiovascular disease who present with one or more risk factors and a calculated 10-year cardiovascular disease event risk of ≥ 10%.
-
FDA Actions
In this section: The FDA adds warning label to testosterone products, approves new treatment for non-small cell lung cancer, greenlights drug for soft tissue sarcoma patients, and gives its blessing to the so-called 'artificial pancreas.'
-
Study: No Connection Between Cranberry Products, Fewer Urinary Tract Infections
The authors concluded that among older women who are nursing home residents, administration of cranberry capsules vs. placebo was of no benefit in preventing bacteriuria plus pyuria over one year.
-
Growing Evidence of Link Between Cognitive Dysfunction, Androgen Deprivation Therapy
The authors suggested androgen deprivation therapy in the treatment of prostate cancer may be associated with an increased risk of dementia.